Tim Kutzkey News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Surrozen, Inc. (NASDAQ:SRZN – Get Free Report) Director Tim Kutzkey purchased 193,548 shares of the company’s stock in a transaction that occurred on Thursday, April 4th. The stock was bought at an average cost of $15.50 per share, for a total transaction of $2,999,994.00. Following the purchase, the director now directly owns 332,885 shares in […]

The race for weight-loss drugs stepped up Monday after Roche said it would buy obesity-drug developer Carmot Therapeutics for up to $3.1 billion.

Carmot Therapeutics Launches Spin-Off, Kimia Therapeutics, to Focus on Metabolic Disease - read this article along with other careers information, tips and advice on BioSpace